Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CBLB | Q13191 | 10/20 | 0.46 |
| ▸ | CBLC | Q9ULV8 | 1/20 | 0.34 |
| ▸ | MAP3K5 | Q99683 | 4/20 | 0.32 |
| ▸ | AKT1 | P31749 | 1/20 | 0.31 |
| ▸ | WNT1 | P04628 | 2/20 | 0.31 |
| ▸ | GSK3B | P49841 | 2/20 | 0.31 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.31 |
| ▸ | OGA | O60502 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29920220 | 0.88 | CBLB (0.51) | CBLBCBLCMAP3K5 | |
| SCHEMBL27085983 | 0.88 | CBLB (0.51) | CBLBCBLCMAP3K5 | |
| SCHEMBL27086202 | 0.85 | CBLB (0.53) | CBLBMAP3K5WNT1GSK3BDYRK1A | |
| SCHEMBL30152750 | 0.83 | CBLB (0.39) | CBLBWNT1GSK3BDYRK1A | |
| SCHEMBL30152693 | 0.82 | CBLB (0.40) | CBLBWNT1GSK3BDYRK1A | |
| SCHEMBL29920297 | 0.80 | CBLB (0.69) | CBLB | |
| SCHEMBL27086339 | 0.80 | CBLB (0.69) | CBLB | |
| SCHEMBL27086259 | 0.76 | CBLB (0.48) | CBLBWNT1GSK3BDYRK1A | |
| SCHEMBL29920284 | 0.75 | CBLB (0.53) | CBLBWNT1GSK3BDYRK1A | |
| SCHEMBL27086025 | 0.75 | CBLB (0.53) | CBLBWNT1GSK3BDYRK1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263399-A1 | CBL-B MODULATORS AND USES THEREOF | SCHRÖDINGER, INC. | 2025-08-21 | — | — | US | disclosed |
| US-12325697-B2 | CBL-B modulators and uses thereof | NIMBUS CLIO, INC. (US) | 2025-06-10 | — | — | US | disclosed |
| CN-117858707-A | CBL-B modulators and uses thereof | 林伯士克莱奥公司 | 2024-04-09 | — | — | CN | disclosed |
| EP-4319756-A1 | CBL-B MODULATORS AND USES THEREOF | Nimbus Clio, Inc. (US) | 2024-02-14 | — | — | EP | disclosed |
| US-20230086064-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS DISCOVERY, INC. | 2023-03-23 | — | — | US | disclosed |
| WO-2022217276-A1 | CBL-B MODULATORS AND USES THEREOF | NIMBUS CLIO, INC. (US) | 2022-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230086064-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | CBLB 1/4885CBLC 3/4885MAP3K5 892/4885 |
| US-20250263399-A1 | CBL-B MODULATORS AND USES THEREOF | CBLB, CBL, CBLC | CBLB 1/4885CBLC 3/4885MAP3K5 892/4885 |
| US-12325697-B2 | CBL-B modulators and uses thereof | CBLB, CBL, CBLC | CBLB 1/4885CBLC 3/4885MAP3K5 892/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.